TG Therapeutics Inc (TGTX)
Return on assets (ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 23,383 | -14,364 | 95,686 | 41,197 | 12,672 | -25,906 | -175,654 | -168,554 | -198,335 | -238,679 | -288,498 | -326,485 | -348,100 | -342,980 | -344,506 | -318,893 | -279,381 | -230,734 | -205,501 | -188,830 |
| Total assets | US$ in thousands | 577,690 | 586,014 | 401,207 | 373,323 | 329,587 | 331,067 | 220,854 | 197,358 | 193,572 | 217,891 | 251,666 | 303,028 | 379,629 | 409,687 | 481,400 | 548,699 | 625,642 | 273,856 | 294,621 | 101,849 |
| ROA | 4.05% | -2.45% | 23.85% | 11.04% | 3.84% | -7.83% | -79.53% | -85.41% | -102.46% | -109.54% | -114.64% | -107.74% | -91.69% | -83.72% | -71.56% | -58.12% | -44.66% | -84.25% | -69.75% | -185.40% |
December 31, 2024 calculation
ROA = Net income (ttm) ÷ Total assets
= $23,383K ÷ $577,690K
= 4.05%
TG Therapeutics Inc's return on assets (ROA) has shown a significant improvement over the analyzed periods. The ROA was negative and fluctuating, reaching its lowest point at -114.64% on June 30, 2022. Subsequently, there was a positive turnaround in performance, with the ROA climbing to 23.85% on June 30, 2024. This improvement indicates that the company effectively increased its profitability in relation to its assets, reflecting better management of resources to generate earnings. However, the negative ROA figures in some periods suggest that there were challenges impacting the company's ability to generate profits from its assets. The positive trend towards the end of the period indicates a potential strengthening of the company's financial position. Monitoring future ROA trends will be essential to assess the company's continued operational efficiency and financial performance.
Peer comparison
Dec 31, 2024